Income statement
USD
Annual
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -488K | 0 | 0 | 0 | 0 |
| Operating Income | -98M | -11M | -3M | -5M | -6M |
| EBITDA | -171M | -11M | -3M | -5M | -6M |
| Net Income | -174M | -13M | -3M | -4M | -10M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0001
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Statera Biopharma, Inc. (STAB) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -855.8%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -855.8%, free cash flow -457.3% with operating margin 0.0% and ROIC -666.5%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines STAB price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
STAB
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
STAB Max Drawdown
-75.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for STAB and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$9.7M
-168.7% YoY
Free Cash Flow
-$6.6M
-43.3% YoY
Revenue Growth
+0.0%
EPS Growth
-855.8%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -488K | 0 | 0 | 0 | 0 |
| Operating Income | -98M | -11M | -3M | -5M | -6M |
| EBITDA | -171M | -11M | -3M | -5M | -6M |
| Net Income | -174M | -13M | -3M | -4M | -10M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|
| Cash & Equivalents | 2M | 594K | 2K | 4M | 4M |
| Total Assets | 21M | 1M | 2K | 5M | 10M |
| Total Liabilities | 23M | 5M | 2M | 920K | 2M |
| Shareholder Equity | -2M | -4M | -4M | -1M | 2M |
| Total Debt | 16M | 2M | 2M | 0 | 0 |
| Net Debt | 14M | 1M | 2M | -4M | -4M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
7M
-43.3% YoY
Capital Expenditures
0
Free Cash Flow
7M
-43.3% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
6677.5%
Debt / Equity
-10.37x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.